-
When it comes to transferring seriously injured patients, there has not been a significant difference in how Level I and Level II trauma centers have traditionally been viewed, according to Sue Slone, MD, FACS, director of trauma surgery at Swedish Medical Center in Denver.
-
In the face of findings at Swedish Medical Center in Denver, that upgrading from a Level II trauma designation to a Level I significantly improves mortality rates, should an ED manager at a Level II facility advocate such an upgrade?
-
As we go to press, a jury has cleared two ED physicians of negligence in a $67 million lawsuit filed by John Ritter's widow Amy Yasbeck in Los Angeles Superior Court.
-
In early February 2008, all the ED physicians at St. Anthony's Medical Center in St. Louis, including ED medical director Ed Ferguson, MD, submitted their resignations over a dispute with the administration concerning the establishment of a physician group.
-
On Feb. 7, a fire and explosion rocked the Imperial Sugar Co. plant in Port Wentworth, GA.
-
This article is designed to refresh and update the community emergency physician knowledge base for the assessment and management of pediatric chest trauma.
-
This multicenter, randomized, double-blind, placebo-controlled trial of hydrocortisone replacement in septic shock aimed to evaluate 28-day mortality in non-responders to corticotropin stimulation.
-
Trauma surgeons at the Regional Medical Center at Memphis carried out a randomized clinical trial comparing a continuous ethanol infusion with a protocol of scheduled diazepam administration for the prevention and control of severe alcohol withdrawal syndrome (AWS) among patients admitted to their ICU following trauma.
-
It is now well established that ventilating patients with acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) using a strategy that limits alveolar distending volume and end-inspiratory static airway pressure results in improved survival, as compared to larger-volume, higher-pressure ventilation.
-
This multicenter randomized trialnicknamed the VISEP studyused a two-by-two factorial design to test two independent treatments in severe sepsis patients.
